title: Effects of changing the type of H2-blocker in the treatment of H2-blocker-resistant ulcers: comparison of roxatidine acetate hydrochloride and other H2-blockers.
abstract: The efficacy of switching from one type of H2-receptor antagonist (H2-blocker) to another, in the treatment of H2-blocker-resistant ulcers was investigated using H2-blockers with five-membered rings (five-membered-ring agents)--such as cimetidine, ranitidine and famotidine--and an H2-blocker with a six-membered ring, roxatidine. By switching from a five-membered-ring agent to roxatidine in the treatment of five-membered-ring resistant ulcers (study I), gastric ulcers were healed in nine of 19 patients (47%) and duodenal ulcers were healed in eight of nine patients (89%). By switching from roxatidine to one of the five-membered-ring agents in the treatment of roxatidine-resistant ulcers (study II), gastric ulcer was healed in six of 15 patients (40%), and duodenal ulcer was healed in 4 of 10 patients (40%). Particularly in the case of duodenal ulcers, the switch to treatment with roxatidine, which has a different chemical structure from the five-membered-ring agents, may be useful in the treatment of five-membered-ring-resistant ulcers.
authors.affiliation: Department of Gastroenterology, Hyogo Medical Center for Adults, Akashi, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Yasutake
authors.forename: M
authors.initials: M
authors.lastname: Amano
authors.forename: Y
authors.initials: Y
authors.lastname: Mizokami
authors.forename: S
authors.initials: S
authors.lastname: Kubota
authors.forename: H
authors.initials: H
authors.lastname: Fukumoto
authors.forename: Y
authors.initials: Y
authors.lastname: Imamura
authors.forename: H
authors.initials: H
authors.lastname: Yokoya
authors.forename: K
authors.initials: K
authors.lastname: Irie
mesh_terms: D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002927:Cimetidine / Q000627:therapeutic use; D004381:Duodenal Ulcer / Q000188:drug therapy*; D015738:Famotidine / Q000627:therapeutic use; D005260:Female; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D011899:Ranitidine / Q000627:therapeutic use; D012008:Recurrence; D013276:Stomach Ulcer / Q000188:drug therapy*
chemical_list: D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D010880:Piperidines; D015738:Famotidine; D002927:Cimetidine; D011899:Ranitidine; C053742:roxatidine acetate